Chae, G.; Choi, A.; Lim, S.; Park, S.; Lee, S.; Ahn, Y.; Kim, J.; Ra, S.; Jegal, Y.; Ahn, J.;
et al. The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study. Trop. Med. Infect. Dis. 2022, 7, 51.
https://doi.org/10.3390/tropicalmed7030051
AMA Style
Chae G, Choi A, Lim S, Park S, Lee S, Ahn Y, Kim J, Ra S, Jegal Y, Ahn J,
et al. The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study. Tropical Medicine and Infectious Disease. 2022; 7(3):51.
https://doi.org/10.3390/tropicalmed7030051
Chicago/Turabian Style
Chae, Ganghee, Aram Choi, Soyeoun Lim, Sooneun Park, Seungjun Lee, Youngick Ahn, Jinhyoung Kim, Seungwon Ra, Yangjin Jegal, Jongjoon Ahn,
and et al. 2022. "The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study" Tropical Medicine and Infectious Disease 7, no. 3: 51.
https://doi.org/10.3390/tropicalmed7030051
APA Style
Chae, G., Choi, A., Lim, S., Park, S., Lee, S., Ahn, Y., Kim, J., Ra, S., Jegal, Y., Ahn, J., Park, E., Jun, J., Kwon, W., & Lee, T.
(2022). The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study. Tropical Medicine and Infectious Disease, 7(3), 51.
https://doi.org/10.3390/tropicalmed7030051